Search research articles
Contact Us
Filters
Showing results (121-130 of 945) with videos related to
Page
of 95
Sort By:
Diagnostic Microbiology and Infectious Disease
|
April 15, 2000
Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America)
D J Biedenbach, R N Jones
The Journal of Antimicrobial Chemotherapy
|
November 7, 2000
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas)
M A Pfaller, R N Jones
Diagnostic Microbiology and Infectious Disease
|
June 23, 2000
Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999)
L M Deshpande, R N Jones
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 13, 2000
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program
R N Jones, M A Pfaller
Antimicrobial Agents and Chemotherapy
|
October 1, 1988
Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin
R N Jones, A L Barry
Diagnostic Microbiology and Infectious Disease
|
January 1, 1994
Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534
R N Jones, M L Sanchez
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|
August 1, 1994
In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies
H S Sader, R N Jones
Chemotherapy
|
January 1, 1995
Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Canadian Ofloxacin Study Group
D J Hoban, R N Jones
Journal of Clinical Microbiology
|
January 1, 1995
Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin
M G Cormican, R N Jones
Antimicrobial Agents and Chemotherapy
|
June 1, 1984
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations
A L Barry, R N Jones
Page
of 95
Search research articles
Search
Showing results (121-130 of 945) with videos related to
Sort By:
Page
of 95
Diagnostic Microbiology and Infectious Disease
|
April 15, 2000
Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America)
D J Biedenbach, R N Jones
The Journal of Antimicrobial Chemotherapy
|
November 7, 2000
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas)
M A Pfaller, R N Jones
Diagnostic Microbiology and Infectious Disease
|
June 23, 2000
Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999)
L M Deshpande, R N Jones
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 13, 2000
In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program
R N Jones, M A Pfaller
Antimicrobial Agents and Chemotherapy
|
October 1, 1988
Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin
R N Jones, A L Barry
Diagnostic Microbiology and Infectious Disease
|
January 1, 1994
Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534
R N Jones, M L Sanchez
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|
August 1, 1994
In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies
H S Sader, R N Jones
Chemotherapy
|
January 1, 1995
Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Canadian Ofloxacin Study Group
D J Hoban, R N Jones
Journal of Clinical Microbiology
|
January 1, 1995
Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin
M G Cormican, R N Jones
Antimicrobial Agents and Chemotherapy
|
June 1, 1984
Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations
A L Barry, R N Jones
Page
of 95